{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T18:28:45Z","timestamp":1778178525799,"version":"3.51.4"},"reference-count":15,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatology"],"published-print":{"date-parts":[[2016]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; Bullous pemphigoid (BP) is an acquired subepidermal autoimmune blistering disease in which there are humoral and cellular responses against the BP180 and BP230 antigens. Dipeptidyl peptidase (DPP)-4 inhibitors enhance endogenous glucagon peptide-1 and glucose-dependent insulinotropic polypeptide secretion with food intake, which leads to insulin secretion, as well as to the reduction of glucagon secretion. Recently, several cases of DPP-4 inhibitor-associated BP have been reported. &lt;b&gt;&lt;i&gt;Objectives:&lt;\/i&gt;&lt;\/b&gt; To report 3 cases of DPP-4 inhibitor-associated BP, one of which is due to linagliptin use, as well as to review all currently published cases of DPP-4 inhibitor-associated BP. &lt;b&gt;&lt;i&gt;Case Reports:&lt;\/i&gt;&lt;\/b&gt; Three patients diagnosed with BP at our department showed a clear temporal relationship between the introduction of DPP-4 for the treatment of diabetes and the onset of BP. One case was due to linagliptin use, while the other 2 cases were due to an association with vildagliptin-metformin use. &lt;b&gt;&lt;i&gt;Conclusions:&lt;\/i&gt;&lt;\/b&gt; This is the first report of linagliptin-associated BP. Furthermore, 2 other cases of vildagliptin-associated BP are reported.<\/jats:p>","DOI":"10.1159\/000443330","type":"journal-article","created":{"date-parts":[[2016,1,29]],"date-time":"2016-01-29T22:01:16Z","timestamp":1454104876000},"page":"249-253","source":"Crossref","is-referenced-by-count":61,"title":["Three Cases of Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors - One due to Linagliptin"],"prefix":"10.1159","volume":"232","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7527-8651","authenticated-orcid":false,"given":"Francisco Manuel Ildefonso","family":"Mendon\u00e7a","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Jos\u00e9","family":"Mart\u00edn-Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jos\u00e9","family":"R\u00edos-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Camacho-Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2016,1,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12616580"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.301"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12174"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2534-0"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04062.x"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0804"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.1073"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3315\/jdcr.2014.1166"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12083"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.9.1075"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1159\/000075040"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2009.04417.x"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.11.2011.5180"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.188"}],"container-title":["Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/443330","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/443330","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T17:36:47Z","timestamp":1745429807000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000443330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,4,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000443330","archive":["Portico"],"relation":{},"ISSN":["1018-8665","1421-9832"],"issn-type":[{"value":"1018-8665","type":"print"},{"value":"1421-9832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}